gene

ALPHA-SYNUCLEIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA-SYNUCLEIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1819Connections

3Hypotheses

3Analyses

50Outgoing

50Incoming

0Experiments

Summary

ALPHA-SYNUCLEIN is a gene implicated in neurodegeneration research. Key relationships include: associated with, activates, therapeutic target. Associated with ALS, Aging, Als. Connected to 529 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	ALPHA
Full Name	SYNUCLEIN
Chromosome	4q21.31
Protein Family	Synuclein family
Subcellular Localization	Presynaptic terminals, nucleus
Molecular Weight	14 kDa (140 aa)
Pathways	amyloid plaques, mTORC1, oxidative stress
UniProt ID	P37840
GeneCards	ALPHA
Human Protein Atlas	ALPHA
Structure prediction	Integrates AlphaFold2, Chai, Boltz, OpenFold, and emerging co-folding methods
Sequence-structure-function exploration	Tightly integrated visual interface for exploring protein functional determinants
Collaborative sessions	Saved sessions enable researchers to share findings with other users
Extensible architecture	Easy addition of new tools and models via the Slivka compute API
Assay data integration	Explore relationships through real experimental assay data or computational predictions
Associated Diseases	ALS, Aging, Alzheimer, Alzheimer's Disease, Ataxia
Known Drugs/Compounds	FINGOLIMOD, RAPAMYCIN, LITHIUM, proCTSD, DEXAMETHASONE
Interactions	INFLAMMATION, PHAGOCYTOSIS, LC3, PARKIN, LRRK2, OXIDATIVE STRESS
KG Connections	1167 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: ALPHA-SYNUCLEIN — AlphaFold P37840 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"activates"| INFLAMMATION["INFLAMMATION"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| ALS["ALS"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| SOD1["SOD1"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| DRD2["DRD2"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| AQP4["AQP4"]
    PARKIN["PARKIN"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_1["PARKINSON'S DISEASE"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    MICROGLIA["MICROGLIA"] -->|"activates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_2["PARKINSON'S DISEASE"] -->|"associated"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    style ALPHA_SYNUCLEIN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1016)

Target	Relation	Type	Str
Parkinson	associated_with	disease	1.00
Parkinson	therapeutic_target	disease	1.00
Neurodegeneration	activates	disease	1.00
Parkinson	activates	disease	1.00
Inflammation	activates	disease	1.00
PARKINSON'S DISEASE	associated_with	gene	0.95
Als	associated_with	disease	0.95
Neurodegeneration	therapeutic_target	disease	0.95
Als	activates	disease	0.95
Parkinson's Disease	involved_in	disease	0.95
Synucleinopathies	causes	disease	0.95
Synucleinopathies	causes	disease	0.95
Parkinson's Disease	involved_in	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Diffuse Lewy Body Disease	involved_in	disease	0.95
Multiple System Atrophy	involved_in	disease	0.95
Lewy Bodies	component_of	structure	0.95
Lewy Body Formation	involved_in	process	0.95
Lewy Bodies	involved_in	biomarker	0.95
NEURON	contributes_to	cell_type	0.95
DOPAMINERGIC NEURONS	contributes_to	cell_type	0.95
Liquid-Liquid Phase Separation	involved_in	process	0.95
Mitochondrial Quality Control	modulates	pathway	0.95
Parkinson's Disease	contributes_to	disease	0.95
Lewy bodies	associated_with	phenotype	0.95
NLRP3	activates	protein	0.93
Dopaminergic Neurodegeneration	associated_with	process	0.93
MICROGLIA	activates	cell_type	0.92
dopaminergic neurons	causes	cell_type	0.90
mTORC1	activates	pathway	0.90
ACLY	activates	protein	0.90
Parkinson	causes	disease	0.90
Lewy Body Formation	causes	process	0.90
Neurodegeneration	contributes_to	process	0.90
Parkinson's Disease	causes	disease	0.90
Neuroinflammation	causes	process	0.90
Neurodegeneration	causes	process	0.90
STAT1	activates	gene	0.90
autophagy	inhibits	process	0.90
Parkinson'S Disease	associated_with	disease	0.90
NEUROINFLAMMATION	promotes	process	0.90
STING	activates	protein	0.90
PARKINSON'S DISEASE	associated_with	disease	0.90
KV1.3	upregulates	gene	0.90
Chaperone Proteins	correlates_with	protein	0.90
Parkinson'S Disease	involved_in	disease	0.90
Lewy Bodies	associated_with	biomarker	0.90
substantia nigra	causes	brain_region	0.90
Dopaminergic Neuronal Loss	contributes_to	phenotype	0.90
Autophagy	activates	pathway	0.90

Incoming (803)

Source	Relation	Type	Str
PARKINSON'S DISEASE	associated_with	gene	1.00
PARKINSON'S DISEASE	therapeutic_target	gene	1.00
PARKINSON'S DISEASE	activates	gene	1.00
NEURODEGENERATION	activates	gene	1.00
PARKINSON	associated_with	gene	1.00
PARKINSON	therapeutic_target	gene	1.00
SNCA	produces	gene	0.95
LAG3	interacts_with	protein	0.95
PARKIN	regulates	gene	0.95
SNCA	encodes	gene	0.95
Autophagy	downregulates	process	0.95
UB-312	targets	drug	0.90
AFFITOPE PD01A	targets	drug	0.90
Prasinezumab	targets	drug	0.90
Cinpanemab	targets	drug	0.90
LAG3	binds	protein	0.90
DNAJB6	suppresses	protein	0.90
VINPOCETINE	attenuates	compound	0.90
PINK1	phosphorylates	gene	0.90
LAG3	facilitates	protein	0.90
SDA-2026-04-01-gap-20260401-225155	investigates	analysis	0.90
TAU	interacts_with	protein	0.90
INFLAMMATION	activates	gene	0.90
NEURODEGENERATIVE DISEASES	associated_with	gene	0.90
PARKINSON	activates	gene	0.90
NEURON	activates	cell_type	0.86
NEURON	interacts_with	cell_type	0.86
APLP1	associated_with	protein	0.85
Autophagy	mediates	process	0.85
LRRK2	interacts_with	protein	0.85
HSPG2	promotes_aggregation_of	gene	0.80
BAG3	mediates_clearance	gene	0.80
BAG3	mediates	gene	0.80
VINPOCETINE	downregulates	compound	0.80
GBA	regulates	gene	0.80
proCTSD	targets	drug	0.80
NNMT	causes_aggregation_of	gene	0.80
ANTISENSE OLIGONUCLEOTIDE (ASO)	reduces_expression	compound	0.80
MICROGLIA	extracts	cell_type	0.80
PARKINSON	regulates	gene	0.80
NEURODEGENERATION	regulates	gene	0.80
AMYLOID	associated_with	gene	0.80
OXIDATIVE STRESS	associated_with	gene	0.80
ASTROCYTES	activates	gene	0.80
SNCA	causes	gene	0.80
TAU	associated_with	gene	0.80
NEURODEGENERATION	therapeutic_target	gene	0.80
SNCA	interacts_with	gene	0.72
MICROGLIA	interacts_with	cell_type	0.72
SNCA	encodes	gene	0.70

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.599	neurodegeneration	What are the mechanisms by which gut mic
H7: Enteric Nervous System Alpha-Synuclein Propagation Block	0.595	neurodegeneration	How does engineered C. butyricum cross t
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.382	neurodegeneration	Which cell types show the most significa

Mentioning Analyses (3)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391]	Lin Aung T, Aung YW, Shi X	Biomed Phys Eng Express	2026	1
A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647]	Tran HD, Shin MK, Yeo XY, Jung S, Junaid	Brain	2026	0
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593]	Boyd RJ, Kho AR, McClymont SA, Loftus SK	Brain	2026	0
Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763]	Ueda J, Uemura N, Chang J, Hirato T, Ish	Mov Disord	2026	0
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889]	Fraser KB, Mirelman A, Mabrouk OS, Omer	J Parkinsons Dis	2026	0
Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116]	Wang Y, Lipton SA	J Neurochem	2026	0
SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927]	Statoulla E, Zafeiri M, Chalkiadaki K, V	NPJ Parkinsons Dis	2026	0
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496]	Panda SP, Saraswat N, Singh V	Neuroscience	2026	0
Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943]	Kabuta C, Hakuno F, Kataoka N, Takahashi	Neurochem Int	2026	0
An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745]	Asmi S, Krishnan A, Alexander SM, Mohame	Ageing Res Rev	2026	0
N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663]	Song P, Chen C, Franchini R, Duong B, Wa	J Clin Invest	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0

ALPHA-SYNUCLEIN

Understanding Entity Pages

Summary

Wiki Pages (21)

GYDE (Collaborative Protein Design Platform)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Pathway Diagram

Outgoing (1016)

Incoming (803)

Targeting Hypotheses (3)

Mentioning Analyses (3)

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

GBA-Synuclein Loop Therapeutics for PD

Experiments (0)

Related Papers (12)

ALPHA-SYNUCLEIN

Understanding Entity Pages

Summary

Wiki Pages (21)

GYDE (Collaborative Protein Design Platform)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

Neuroresilience Mechanisms and Evidence

Therapeutics

NPM1 Gene

Pathway Diagram

Outgoing (1016)

Incoming (803)

Targeting Hypotheses (3)

Mentioning Analyses (3)

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

GBA-Synuclein Loop Therapeutics for PD

Experiments (0)

Related Papers (12)